1. Description
Chemical Properties: A synthetic analog of the natural heptapeptide, with the amino acid sequence Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂. C-terminal amidation enhances molecular stability. Molecular formula: C₄₀H₅₀N₈O₁₀. Molecular weight: approximately 802 Da. Its primary target is the μ-opioid receptor, exhibiting high selectivity with no significant non-specific receptor binding. Its analgesic potency is 20-100 times that of morphine. The D-alanine modification significantly enhances resistance to peptidase degradation, prolonging the biological half-life. At human body fluid pH (7.2-7.4), activity retention rate ≥90%. No contraindications for combination with commonly used anti-inflammatory or neuroprotective drugs. Can exert effects via peripheral or central administration.
Physical Properties: At room temperature, it appears as a white to off-white, loose powder with no odor and no visible foreign matter. It exhibits excellent water solubility (solubility ≥20 mg/mL), dissolving rapidly in aqueous media such as pure water, saline, and phosphate-buffered saline (PBS). It is slightly soluble in methanol and ethanol, and insoluble in non-polar solvents like ether and petroleum ether. Store at -20°C in a dry, sealed container protected from light. Avoid repeated freeze-thaw cycles. Both research and pharmaceutical-grade products exhibit ≥98% purity (HPLC-assayed), with single impurities ≤1.0%, endotoxins ≤0.05 EU/mg, and heavy metal residues (lead, mercury, arsenic, etc.) ≤0.1 ppm, meeting standards for pharmaceutical raw materials and research reagents.
Source and Preparation: Natural phyllomedusin is extracted from the skin secretions of the South American leaf-frog (Phyllomedusa sauvagii). Due to low natural yield and high impurity levels, both industrial and research applications employ solid-phase peptide synthesis for artificial preparation. Using high-purity L-amino acids and D-alanine as starting materials, the synthesis involves condensation, deprotection, precise peptide chain assembly, and C-terminal amidation modification. The final high-purity product is obtained through multiple HPLC purifications. Reaction conditions are strictly controlled throughout synthesis. Product quality is validated via mass spectrometry (MS), amino acid sequence analysis, and opioid receptor binding assays, ensuring no synthetic byproducts or residual natural extraction impurities.
2. Application
1.Core Areas of Pharmaceutical R&D
Novel Analgesic Drug Development: As core lead compounds, these are used to develop peptide analgesic formulations for severe postoperative pain, cancer pain, and neuropathic pain (such as postherpetic neuralgia). Formulations include injectable solutions, sublingual drops, and sustained-release topical preparations, suitable for patients with tolerance to traditional morphine-based drugs or at risk of addiction. Currently in preclinical research and partial clinical stages.
Interventions for Neurological Disorders: Preclinical studies for epilepsy, Parkinson's disease, ischemic stroke, and traumatic nerve injury. Mitigates neuronal damage through neuroprotective mechanisms, exploring adjunctive therapeutic potential in neurodegenerative diseases and acute neurological injuries.
Opioid Withdrawal Aid Development: Leveraging its low-addiction μ-opioid receptor binding properties to develop withdrawal-aid formulations for opioid dependence. These alleviate withdrawal symptoms like pain and anxiety while reducing side effects associated with traditional detoxification regimens.
Veterinary analgesic drug development: Develop highly effective, low-toxicity analgesics for livestock, poultry, and pets. Tailor clinical interventions for postoperative and traumatic pain in animals, avoiding the high toxicity and residue issues associated with traditional veterinary analgesics.
2. Research Tools and Reagents
Opioid Receptor Pharmacology Research: As a specific ligand for the μ-opioid receptor, it serves as a core tool peptide for molecular and neuropharmacology studies, enabling receptor subtype identification (μ, δ, κ) and investigation of signaling mechanisms.
Analgesic Drug Screening Models: Used to construct in vitro cellular models and animal pain models (e.g., hot plate test, tail-flick test), providing a basis for activity screening and potency evaluation in novel analgesic drug development.
Neural Signaling Pathway Research: Used to explore pain transmission and neuroprotective signaling pathways (e.g., G protein-coupled receptor pathways), supporting fundamental neuroscience research and drug target discovery.
3. Clinical and Aesthetic Medicine Applications
Aesthetic Surgery Postoperative Analgesia Support: As a research-grade raw material, it is used to explore short-acting local analgesic formulations for aesthetic surgery and minimally invasive procedures. Local administration alleviates mild to moderate postoperative pain while avoiding side effects of systemic analgesics, such as drowsiness and gastrointestinal discomfort.
Chronic Pain Clinical Research: Employed in hospital pain clinic studies to evaluate its efficacy in managing chronic non-cancer pain, providing data to optimize clinical pain management protocols.
3. Main Efficacy
1. Core Efficacy: Highly Selective, Potent Targeted Analgesia
Mechanism of Action: Piroxicam binds with high specificity to μ-opioid receptors in the central nervous system and peripheral tissues (without binding to δ or κ opioid receptors). It activates Gi/o-coupled G proteins, inhibits adenylate cyclase activity, reduces cAMP production, simultaneously blocking voltage-gated calcium channels and opening potassium channels. This inhibits the generation and conduction of nerve impulses in nociceptors, thereby blocking the transmission of pain signals to the central nervous system and achieving potent analgesia. Its advantages include potent analgesic activity (far exceeding morphine), rapid onset (effective within minutes after central administration), and minimal accumulation due to rapid degradation by metabolic enzymes. It exhibits significantly lower addiction potential and tolerance compared to traditional opioids like morphine and fentanyl.
2. Key Efficacy: Central and Peripheral Neuroprotection
Mechanism of Action: By scavenging reactive oxygen species (ROS) within neurons, it inhibits oxidative stress-induced neuronal apoptosis. Concurrently, it upregulates the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), promoting axonal regeneration and functional recovery in damaged neurons. It alleviates neuro-tissue edema and inflammatory damage caused by ischemia-hypoxia (e.g., stroke) or traumatic injury, reducing neuronal death and preserving structural integrity of neural tissues.
3. Synergistic Effects: Suppresses neurogenic inflammation and aids analgesia
Mechanism of Action: By inhibiting the release of pro-inflammatory factors (TNF-α, IL-6, prostaglandin E2) in peripheral neural tissues, it blocks the onset and progression of neurogenic inflammation. This reduces the sensitizing effect of inflammatory mediators on pain receptors, achieving dual “analgesia + anti-inflammation” effects, with particularly pronounced improvements in inflammatory and neuropathic pain.
4. Additional Benefits: Regulates gastrointestinal function and reduces opioid side effects
Mechanism of Action: Unlike traditional opioids, PEP has low binding affinity for μ-opioid receptors in the gastrointestinal mucosa. It does not significantly inhibit gastrointestinal motility or glandular secretion, effectively preventing constipation, nausea, vomiting, and other gastrointestinal side effects associated with morphine-based medications. It also mildly modulates gastrointestinal smooth muscle tone, offering partial relief from opioid-induced gastrointestinal dysfunction.
5. Safety Advantages
As a peptide compound, Pifentanil exhibits high biocompatibility, lacks immunogenicity, and does not trigger allergic or rejection reactions. Its metabolic products in vivo are amino acids and small peptide fragments, enabling rapid absorption and utilization by the body without hepatic or renal toxicity. Acute/chronic toxicity studies confirm its broad safety margin. Its core advantages lie in low addiction potential and low tolerance development, addressing the primary clinical challenges of traditional opioid analgesics. It stands as an excellent candidate for novel analgesic drug development.
